Tags : STADA

Bausch + Lomb Signs an Exclusive License Agreement with STADA

Shots: STADA and Xbrane to receive up front and milestones upon approval and launch of the Xlucane in the US and will be eligible to get an equal share of profits from sales of the biosimilar. The companies aim to obtain all currently approved indications for Lucentis in the US and Canada Xbrane and STADA […]Read More

PharmaShots Weekly Snapshot (February 24-28, 2020)

1. Companion Medical’s InPen Diabetes Management System Receives the US FDA’s Approval for Fixed Dosing and Meal Estimation Published: Feb 28, 2020 | Tags: Companion Medical, InPen Diabetes Management System, Receives, US, FDA, Approval, Fixed Dosing, Meal Estimation 2.  Takeda’s Vedolizumab SC Receives CHMP’s Positive Opinion as a Maintenance Therapy for Moderately to Severely Active […]Read More

STADA Acquires GSK’s Consumer Healthcare Portfolio to Expand its OTC

Shots: STADA to acquire GSK’s 15 well-established consumer healthcare brands including Venoruton, for venous treatment, Coldrex cold remedy, Cetebe vitamin C supplements, Mebucaine sore throat range and Tavegyl allergy brand The acquisition will strengthen STADA’s OTC portfolio and accelerates its growth in European countries. The transaction is expected to be completed in Q2’2020 The acquisition […]Read More

PharmaShots Weekly Snapshot (December 02-06, 2019)

1.  Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders Published: Dec 05, 2019 | Tags: Sage Therapeutics, Reports, Results, SAGE-217, P-III, MOUNTAIN Study, Major Depressive Disorders  2. UCB Reports Results of Bimekizumab in P-III BE SURE Study for Moderate-To-Severe Chronic Plaque Psoriasis Published: Dec 06, 2019 | Tags: UCB, […]Read More

Insights+ Key Biosimilars Events of November 2019

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar […]Read More

STADA to Acquire Biopharma’s Pharmaceutical Prescription and Consumer Health Business

Shots: STADA to acquire Biopharma’s pharmaceutical prescription and consumer health business including local manufacturing operations and ~300 new staff. Biopharma will retain its blood plasma-based business and will focus on its development both in Ukraine and outside Ukraine The acquisition will complement STADA’s European growth strategy and allow STADA to become a major pharma player […]Read More

PharmaShots Weekly Snapshot (November 04-08, 2019)

1. Triumvira’s TAC01-CD19 Receives FDA’s Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma Published: Nov 07, 2019 | Tags: Triumvira, TAC01-CD19, Receives, FDA, Fast Track Designation, R/R, Diffuse Large B-Cell Lymphoma 2. Janssen Reports Submission of MAA to EMA for its Investigational Ebola Vaccine Regimen to Prevent Ebola Virus Disease Published: Nov 07, 2019 | Tags: […]Read More

STADA Signs an Exclusive Commercialization Agreement with Alvotech for Seven

Shots: Alvotech to receive up front with subsequent milestones for the next five years. STADA to get exclusive right to commercialize seven biosimilars in all key European markets and selected markets outside Europe Alvotech will remain responsible for the development, registration and supply of the biosimilars within the EU. The collaboration will expand Alvotech’s biosimilar […]Read More

Takeda to Divest its Portfolio of Select OTC and Non-Core

Shots: Takeda to receive ~$660M for divesting its 20 select prescription pharmaceutical and OTC products traded in Russia, Georgia, and several countries within the Commonwealth of Independent States. STADA to get rights, title, and interest to the products in the portfolio exclusive in these countries. The transaction is expected to close in Q4’19 Additionally, Takeda […]Read More

Top 20 Generics Pharma Companies Based On 2018 Revenue

The global generics pharmaceutical market is continuously growing and increasing with its accessibility & benefits offered as efficient and economical drugs, are always needed in the market. Generics are approved copies of small molecule drugs which contain the same amount of active ingredients, dosage form, safety, strength, route of administration, quality, performance characteristics, as of […]Read More